# 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/32p-atezolizumab-plus-albumin-paclitaxel-based-regimens-is-an-optional-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | J. Wang,Y. Wang |
| Citations | 1 |
| DOI | 10.1016/s1556-0864(23)00286-1 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.jto.org/article/S1556086423002861/pdf |
| OpenAlex ID | https://openalex.org/W4362579513 |
| Type | article |
| Year | 2023 |

## Paper authors

- [J. Wang](https://scholariq.org/researchers/j-wang/)
- [Y. Wang](https://scholariq.org/researchers/y-wang-3/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.